0001171843-23-006258.txt : 20231016 0001171843-23-006258.hdr.sgml : 20231016 20231016080041 ACCESSION NUMBER: 0001171843-23-006258 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231016 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231016 DATE AS OF CHANGE: 20231016 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aptose Biosciences Inc. CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32001 FILM NUMBER: 231326239 BUSINESS ADDRESS: STREET 1: 251 CONSUMERS ROAD STREET 2: SUITE 1105 CITY: TORONTO STATE: A6 ZIP: M2J 4R3 BUSINESS PHONE: 647-479-9828 MAIL ADDRESS: STREET 1: 251 CONSUMERS ROAD STREET 2: SUITE 1105 CITY: TORONTO STATE: A6 ZIP: M2J 4R3 FORMER COMPANY: FORMER CONFORMED NAME: Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) DATE OF NAME CHANGE: 20140905 FORMER COMPANY: FORMER CONFORMED NAME: LORUS THERAPEUTICS INC DATE OF NAME CHANGE: 19990308 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 8-K 1 f8k_101523.htm FORM 8-K Form 8-K
0000882361 False 0000882361 2023-10-16 2023-10-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 16, 2023

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada001-3200198-1136802
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

251 Consumers Road, Suite 1105

Toronto, Ontario M2J 4R3
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Shares, no par valueAPTONasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 7.01. Regulation FD Disclosure.

On October 16, 2023, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.
   
99.1 Press Release dated October 16, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Aptose Biosciences Inc.
   
  
Date: October 16, 2023By: /s/ William G. Rice, Ph.D.        
  William G. Rice, Ph.D.
  Chairman, President, and Chief Executive Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Company to Hold Clinical Update Webcast; Details Forthcoming

SAN DIEGO and TORONTO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that two abstracts on tuspetinib, Aptose’s Phase 1/2 myeloid kinase inhibitor in development for acute myeloid leukemia (AML), have been accepted for poster presentations at the European School of Haematology (ESH) 6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment, being held October 29-31, 2023, in Estoril, Portugal.

Aptose is planning to hold a clinical update webcast on October 30, 2023, to provide additional up-to-date data on tuspetinib. Details will be forthcoming.

The posters accepted for presentation are listed below and can be viewed beginning October 29, 2023, on site at the ESH poster exhibit hall and online on the Aptose website here.

Poster Presentations

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy as Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

  • Abstract Summary: Tuspetinib (TUS) is a potent once daily oral myeloid kinase inhibitor of SYK, mutated and unmutated forms of FLT3, JAK1/2, RSK, mutant forms of KIT, and TAK1-TAB1 kinases that mediate dysregulated cellular proliferation in acute myeloid leukemia (AML). As a single agent, TUS was well-tolerated and highly active across four dose levels among diverse AML genotypes and delivered a 42% CR/CRh across evaluable venetoclax (VEN) naïve patients at the 80mg daily RP2D. In the ongoing APTIVATE clinical study, tuspetinib is being evaluated clinically as monotherapy (TUS) and in combination with venetoclax (TUS/VEN) in a global Phase 1/2 trial of patients with R/R AML. The TUS/VEN doublet also has been well tolerated and has achieved multiple responses to date in patients who previously failed VEN (Prior-VEN failure AML), including Prior-VEN failure patients who also previously failed FLT3 inhibitors, all of whom represent emerging populations of high unmet medical need. Notably, TUS targets VEN resistance mechanisms and appears to re-sensitize Prior-VEN failure patients to VEN.

Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax

  • Abstract Summary: Tuspetinib (TUS), a once daily oral agent, simultaneously suppresses a limited set of key oncogenic signaling pathways that mediate resistance to acute myeloid leukemia (AML) drugs by potently inhibiting SYK, mutated and unmutated forms of FLT3, JAK1/2, RSK, mutant forms of KIT, and TAK1-TAB1 kinases. TUS as a single agent produces complete remissions in relapsed/refractory (R/R) AML patients, and the tuspetinib/venetoclax (TUS/VEN) combination doublet achieves multiple responses among very difficult to treat AML subpopulations in the ongoing Phase 1/2 APTIVATE trial. We investigated the effects of TUS on key elements of the phosphokinome and apoptotic proteome in both parental and TUS-resistant AML cells. In parental cells, TUS acutely inhibits key oncogenic signaling pathways and shifts the balance of pro- and anti-apoptotic proteins in favor of apoptosis, suggesting that it may generate vulnerability to VEN. Indeed, acquired TUS resistance generated a synthetic lethal vulnerability to VEN of unusually high magnitude. Concurrent administration of TUS and VEN may eliminate cells that carry this form of TUS resistance at the start of therapy and discourage the emergence of TUS resistance during treatment.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit www.aptose.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the Company’s growth, plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

For further information, please contact:

Aptose Biosciences Inc.  LifeSci Advisors, LLC
Susan Pietropaolo   Dan Ferry, Managing Director
Corporate Communications & Investor Relations  617-430-7576
201-923-2049Daniel@LifeSciAdvisors.com 
spietropaolo@aptose.com  

 

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 16, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 16, 2023
Entity File Number 001-32001
Entity Registrant Name Aptose Biosciences Inc.
Entity Central Index Key 0000882361
Entity Tax Identification Number 98-1136802
Entity Incorporation, State or Country Code Z4
Entity Address, Address Line One 251 Consumers Road, Suite 1105
Entity Address, City or Town Toronto
Entity Address, State or Province ON
Entity Address, Postal Zip Code M2J 4R3
City Area Code 647
Local Phone Number 479-9828
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol APTO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

XML 8 f8k_101523_htm.xml IDEA: XBRL DOCUMENT 0000882361 2023-10-16 2023-10-16 iso4217:USD shares iso4217:USD shares 0000882361 false 8-K 2023-10-16 Aptose Biosciences Inc. Z4 001-32001 98-1136802 251 Consumers Road, Suite 1105 Toronto ON M2J 4R3 647 479-9828 false false false false Common Shares, no par value APTO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_101523.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_101523.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "dts": { "inline": { "local": [ "f8k_101523.htm" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_101523.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_101523.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001171843-23-006258-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-006258-xbrl.zip M4$L#!!0 ( !1 4%?=1I-%J T &(B + 97AH7SDY,2YH=&V]6FES MVS@2_07['S!*3=:NTF4[D\-V7.O82N*-K[649.8C1$(2)B3!!4 KFE^_KQN@ M1$FV,U-;NZFR0X$X^GC]NAOR\4_G-V>CWVX'XN/HZE+7$F6IU>[^O! M6:]W/CH/+UYT^V)D9>&TUZ:06:\WN&Z=',]\GHE,%M.W+55T/@]I2,GTY-AK MGZF303J5]KW.=#$][H6AXUQY*1)3>%7XMRVOOOL>[7(DDIFT3OFW_N_[+=$+ZXH9*[>MCX,K@=WIZ.;N]9JBZLA2_BZV^]W7[WL[W7W7O??O."5 MO2#,V*0+,9XF)C/V;>O9A/]!U%(XO\A4D*(C,STM#H75TYD_PEOGK2FF)X-? M/UZ\NQB)-V^Z>\>].'C<*Q]9GD F96G]! +6,^BYX_0?ZE#LO2B;VY^6WC@E MSF CG=S">6]$6-%PXYV3X7T8E!94RI9B&$R,R839B(^2I5+ M#R6G"[$S&'[<%2_]3%R0/(4,;A-GII@HJXI$-70AZ?Z42G'%F+ MULGP]%J<7PP^W+ YX.Z;Z]%-6]PDOBO$WLNVV._O'PBQ\^'RYMU 7 ^^#K]> MW UV1:,237HZ6"#IBIWGSU[O[_>/PGO^L'<5Y.E2CA-^U@:&&*)/@A MB:9*U;W*3 D#B!D EF%$3]@37DMRJ;&PWS==2 BOBYD>:V^L(Q-[J^#O6>U; MG8B<[24+*.C:F)+*!0Q5F KJIE (T_W<"#F&J67B'<01OG*E\A!WW!8K&^R] M.G+B=D:'[O7V1;Z D#K=D@-/M08Y)!83#,FD@JOK%9FJOJE<2[%S>G6YVQ8S M>:^ 655@7J)*TI 6E<8!2F0H0C*#TA&:R0G_-:+A');I*LIT62(> GE$JG:B!(,6= "\/:. 6B%+5"&DYB&D MR).U ?]^G0L*ZVYUZD2,DTC0V-EQYL.KTZ)1-9 T%W&YEQG&;'+9!6CW4=E M'L%/P8=NP[$-CPIIE2[MXE TS+(S^CS<):1+ M>)*R-A$DP5*#")GY'F4>:#G\[5-;Y)5GGB0K547]"=#+'XQJS.Z/3=7CS-!,H< AN(.7P^QY:(S(SVB@K%E #S:="F3*QQ M#H)75J0$Z(RH%QOF< _RQCVB#V!'S8.-#3G)\2ZIRN@=[2E>[/\LSNYZ9W>S M>CMU+[-*CB'/_0I6.U\&U[NHK9X_VS]X]_-I]-/=[?YY%Y#F M<4AB*'J1&2^^G(X&*\)RODH7[0;5D-\#?P81V*QQ=L91D#>B($"%U(&-$PZ' M8'*&>%-T3.RQ^.0,,O@L3705*N!TGOCDS7%41E<0M8N8)A/*+<@8&E M"YF+'"4V'"6)]V8:#DD!L,SK$@8%=91@#<7IF@D7(JV.G1$]JWMM*@=])S F M%M.Q.[=6&]NA1QJM+'MUE]))DE4IF6Q[QMJ^+/#VYA0-C2H"L,_8%%B20]I( MUD+ERD[IE-*451:S,:81'"G(5 @*\FJA5-H5U\8#08N 92_M5$$.$@X;@N\I MBV(%"OE"NSR 4I;(Z:&0L:J#8ZF#^$,]I1BF8GR9/C.-7U7VEWCXACCE43(^ MH\0.;PT7!6#G45%=*E! )KY460%OC]&Q>"YO5PS\_^%(>&J+&B-].$UXDX4* MGG9526XDT$DDVUP31-$^D?^^J057H%@(W1S5BAF[6?K97"XV^*[A.VC\%*V) MU%93!,!O,'(I^C4K4KPI[DL%5XV8( MZG6.77':DFV9W+IHM# 7IWH]93O3*H6V@FO^"9L+,A(<5*9R#BX,TZQR9AQ^ M8%F3JQBH!N43!0/LZ14-0XXQB!DFHCXE-J?8M%-#)DA/.=)Q9EA.Y*% $PRH M%5+1]Z%L"*\A*&*GFD[) M2E1B$_110N;HF2 !<[NXWXI[\ \42L%ZP$7R[TI36B5U&M%2+Z=\ZY94D@4J M>6A+DJHJ*E=QXF.6S>6TT,B8JDN-3%)9,B"J>)3AFLB"019=28K3+B2ZHI O M2'8V=5 KD188\S/M.)SJ=0V18U;')^LC%):U)W$82@YJ9!E'E!Q4-/S&-FEE MV99U@_37N/IT;"H?B_4?5]H/-/1<2&[TWF,-""2S8KWMQO]@1@X-T^S!5YTZ M)SB4W(Y:)R)4>KV=^QA:=5??#J6$I#H0W($\=***VJ%$V>@ 50$YZ -UJ;B?"?D?,@5J0R#@ \P2]*A[O3425,NNHN!) MJI@%2@^4$-[!DUQHA?A9$T''(A*EKX9+0[5$?C(@+O!G&?K3[S 6^-*M:<=E M$=TX;/CDD3N-"G%EM^X3'KO@.&R6DCL?KUX?Z7HTA3H7:\F.(_L99 MJTYC;BQ8SE7)C$(EWHB20711U?>E[7H\G+,YRH>EFZ-TP;0Y-C/E\@XV#CFP M3;:]^*%!N&IS*!2DB,)ZUX:VL#)U\)"9^1VVZ*("AYYK-I^ F(%^]-QU%J:K MJF4,.%*8/#*I/'4KB"%NDZD8P4=4<+_'"5:[;RX6P.!7 I2OV96F%@HYS$E+ M!?Y84F!5)5V:B:+*Z2(,<*):)><6A1:2?F:84@@'D :I,$+T. M[$3=/:KSBHI9CK\9WS!SN["4CQ*)IH0 %<>5H]Q'R,%N)M=)FW,GZ)80!8P9 MU"_++R:<28CHMO4*.*%R@1G@BI+"A(F"JG*X$/FN0I"1>3%,! :3H@[&R:6R M3!-<:MBZDL[K5G!,H0D"UEPT+6_-Q<2BE^5S@D/^U'Y(HXG58Y4&DM\D@6ZD MD">88\@P1:KGS9GF0AT%[8+G,;QNH%I\M+UM>AN0SJ'=="TW;V"&R"Z.@AJX M(%A[:NI;=]A>O ]6;7$] FM.^-NU"-,E#378)]YED2?J!N=SP;3#S(DN>#67 MKR>_4_\^9=J)753(V-DBU,]4C3U!D%2=< 5C$$6);V_XFWGV'LUOTZOLR[#S MRD.$75UPH?'TB03U7-+E][*]X4L8?M[B>=)QCAF&*3A05NC]XA#[1#&TS#BC MSHKS%Z 8[^+]#P0B&J:K<9+'JM@[("R1![AE2^B[FG .)%^8*E3O;H.2^&(^ M6#.$@4S@*!* +Z'6C$KBKQ-3B+H0+H^8FHK 1)?J9# M?#^9JVEJS*$U%39"<\$%'T'LZ:BGG0,[; MUJR:ZF+S>^1E]2/J\4;?M/V2OAE=CH8O-7E6:,VH^U[K-!#2@TK!Q*[U0K32XDB,T@EGA3N'$O>*W3 ;=%P?]SJM? M7KW\T?G[_;W.F_V#SG[_Q9O'U=,J^TG?P'4$L#!!0 ( !1 4%<#1Q0O M( T * X . 9CAK7S$P,34R,RYH=&W5&_USVCCV7]'1Z5XR$P,&\@%- MV$D)Z;';? S0V9W[94?8 C0UEE>2 ]Q??^])-A@P!+(T=]N9MK'U_+Z_]*1< M_SR;!.2%2<5%>%-PB^4"8:$G?!Z.;@JQ'CI7A9^;UV,-4 9JIO"6.NH42I- MI]/BM%H4>-V83ZO!0:1IZ;/%1P,/O MV_'CZ@)T( .^ HIO4B+5T@9J6/67'V2!+TIV<054YX*>6U"=@G(E:A7W&F!(&P8]9O7FNN ->]!M^3*^?6Z9)^O2W9U(/PY47H>L)O"4(1@+/X? MUB!N.=* P>8.$(F2?8(W/&HB"2?LC]WT6FA\!X#&>,,D]$M() M?LIXHQT"W7F+@1 TZ(0^F_W*Y@7B 4DVTUVT K)X]6NA688_5U>5ZH5[75I! MUR1KZ*W#W!3 R1H# 6JEX9 &Z 5+PK<3%OKP5]\'=)1/\!Z_6:=EGC-2@2LP M";F)*6 #W:VA3!X!3,0DA\;8^-(HG#K@OO6R6W:+,^47DE4]CX CQ2=1P$![ MI544@+.T3L0\*Q%+^VB23B/AGW!_R7^ZQHR.%X_[GN&7'O4B_7*XM>?6WP*8K"[(+.J45%2Q0 MQ2&W^OC6NULJ8\*HBB5K)CFP 8LI@G1I@1$Q;*+KC2GH?Q-C(I)9/1 E,/&\ MCA9B#)2] FM\D&HAWRS-)@9\>\=",>%A+N:]I5I%4EH38E7\THH/VY!*> >M\) M?$.4"+B_6$S1V75WN3[EOAYCYBM_!#(_?7 ORI\2+NV_41[9&M(U+Z:,C\:Z M 70"P(8>ZM" C\(&\2!PF%P(9-B[R)&P; 3\]MCIM^](KW_;;_>N2]&1"9>W M$NZU6]^ZG7ZGW2.WCW>D_7OK7[>/7]JD]?3PT.GU.D^/[\/-A>'F-ZK&T 5J M$9Z1NV*K2"KE\UI]E8,<[(7F'^M_CL]UGO$LU_=/W8?U*K6L17?"B[$4]:$6 MY)>G;O\]*3_'4L4TU$0+TF,>=H[$K1(A MB7M^XI]>#R0I-<60Z#'#]5ARS9DB[9DWIN&(D5M/$UAVZ]7:=K;+1V<;JQO2 M[;)(2$U.TF=&(7,RI0E[ 7Q$FF7FGS9L+MK5_/B 8@(\CGTZGP,>%A9RW.[9 M%-*VK:_Y_O?D:3& AL&]."-8FH_AC >YYIORYG8#+?85#1)'T$AXL$=(FM<= M;6J7C;C"3_4CK.1KZC;20C'RF0OE<=.RD4[H%7%:$?!W\"1Y>B3K:3H(6(HE6S937J6U XVU6+P+ MV#!]54AJ\4T!MOL>"P(54<_L^)/GB/I^\@S49$KJA4G-/1JD3(.&T);:7^.E M6OV8>,3A,;SA&YDPPXUL@_DC*B,I7I(=V6JH6?\!1Q 2HM=L9GL:HJUE@5O" MW^).+1I2GVYZC_;S!*SE"9CG2YM"O^K\]SQ@L 998-OV##:M.$O9E]EC6F.= MV3Z==9*=BF>TO8OS^I7CNM6+JW(EG_62E@>YVSX6@% U#H!5Z0D*D22_0!U2 M/K?E"F)WQ5E.UY6X)XV6F$RXPBD:0?L1JX:W8NL4N\5>D;1AKRKFP/*JBLFC M*)YF-%8R^:!Y_0_'(<\"MGH!N?5]:/L52=S^ACC.7\F"MC3D-*UO\>^$M^2_ MKSQD;KZ[5,Y=$"!4B$>1KJ#^&>G%'&SINN7S8R?ZXTO8@A^?9%],PWSY2%]( M>"W6)3G;T6F8%*C0H3$%(N&\_)/MF?6A\HOI-:MD@V#F?8PS;M'-UY2I]-(@$!_EJ %'D%XM&?0C6K^PLC3 M$***J5-R C(0%,(6:1-+8Q&FD?Q* !UU'WBR5?7H4;>2T>W*OJA=KNOY=+LI MOPI(KT;,76F[=EEWZE>5JW>(N,1HR_[OGPKP!"PRI@@-DV?057E!C T*@4Z; M L]9JR'78"]L'-_3:.F\XH#2H;$;JJ@U&"LDX"J M= MSK+83M=L:,^_[0,R@V]Z_I&#KF;SA(9:R;%_]VNX6"9H=)(T@Y4628S$' M#LB !6**@N-B.EXG0QZ@8W %7J(94/-Q=ZKX) XT#9F(53 G"NJH&L[-E\D' M8@"\TK0GP(5,3Q\#'E!V.$_7AB( XO@=IF&.=5\U]NO-=\J[T:?]F/[\8[XK MKG\_X;X?Y&S7UNL1COX'%#2BP2[9:O0;[/C!"-@!FRK_JX6_.=RLG@=#_]6]B_ MIP4Z2L5,_M_:H>-?XW%) ME03I;%$TQS>V,NX_>-"& MJ;<, 0YBK%+=AS%)3DPFJ$9=+(T+\*3IF,.; MI;OMFYD.]0& !R?$T,;^U>:-X^]Y_^)QQM#'+!V)L#C%2S:8HT!P#@)J#R.],K4JRD3GM^C FT#5^., R^2#'58]CQ3R+LZ]\GCW9"'^L$ M9,$Y;-=P8P-@W\'5F9E,KNTZ8 ]#0\)2CD>68R_AF"KBLR$/[2F#[6K+YV3S MN&UYRE8E)[A-O?QD.ML4F)OSB0C/)W!G:6M69>!4DSC,@1W&NXC?&>[P%YR:Y#H?W]CMCL&U6 % M'5PK%*:\QXH9*. KV5/CN1XW)=]>#T*M&EK!'(E/.9!&W8=LBEXE&>R2X3MP M6!IZN%N@GCG 06"\K.E3Z2N[F_:W]1;5$[KH+;*>6"0+Q4=;K[1L'?#F5JC: MXE[*VE64#/:(CI@SD(Q^=P8,Q >#TF!*Y^K0F=$B.^$ HZ/9Q Y74GI;K]Q8 M+-=@-A&.FO@AN2R6W2+ILE$ER4$<-9]"LGXB M?6;4W\VF*>B^?4+!>#AHE> Z5+$S@H.YR$Q,;"G'=*8UE'D AFS'P+(4,\J8 M#[@F]7K1!8?Q[>0F/9%)0"'!@=,N+N-=7^MR7UC()'A7)P3N M8NLWGXLF):4C(BL #Q>W73%_XJL5_I>\KC.9\*[&D#),? P89&((.S-I@H>? M/EQ5*N5/0QXPW_SL?C+1 3X="<7,+'KATU=[9MDSY(-.;/2=X <)F2QP0NT4 M^P^9<*ABU'U&VB6[*WK.*A@U@L&;S,:V3DJ2LI+E[0RC?3U S["S8Y$]'#=< M#3"7&(7C.(YI5!"8#YA(#L^]56Z,%)8=:_WLQ; #8Z1N8N1^D8G,,0ENY91Q MP,38ZL!@61G\;8[Q#CMQW]6%+?/&*]U:NCLH1[.]/UJ%2[KMW1]<4V)OWK+9 M^(]ZW2V.]:30Q%"Y+M'7>\JW<9E/]-E$<#>)8-_X]>:-&MH\0#JW7/M!(K0$ M[%[(,Q01R%;0)E'/G$C=44WM&?()FPR8C_&.J2U)4AUS9Y_@I7WB)_>*\J8% MV?C8>=7S[U 7>] ;40T%[)!3AUU7,'J=+X^W_6_=]N[6;/6*FVV3_HRY3++% MOID[I[_R8\A['HVQ)S*]LCVJ22J( @%@0=C;0P,&*7.(N1$1F62< & I@AY* M6'0TUF,A@7N_N/LHXNCW?_;-2#FF@"8!R8=FSD),'7Z'^>-_)9-2'F,R^Y,-.P#HE)*>?TJEE2 M)?(;#P).)^0+-*;<@\[P>5R\*UKL^__[/FK/Y_5]:+?&E$.3%@)1R'3F%T#. M3$?2&G,VW+BT(,F[>V)V%)WVQ.9WB9;[E672OJA=.NG5@47SO>Z(-I]G3\]+ M^!M1^.M1>A(T_PM02P,$% @ %$!05X4E5ZNP @ U0L ! !G;G'-DM5;1;ILP%'W>I/V#Q3MQ:+1*B4BKJ=6D2EDWK:NTM\D! M0ZT9F]FFI'^_:\ ))"0*M.7)7)]S[KWFV":\WF0;BYN_/0]=6GCZ&.GFA&$#"$7GI/QN0+C,NRG)2SB50IOIA. _S[ MV^JAPGDU<+'A3/SM@P?S^1Q7LPYZ@-RL%7?2,VRGUT33K3+,LA-X)K0A(NK@ M8[,EM,&?<3W9@;)>Z&4-90X:TSVCR>LDB(H.5 XV/XC(G"K#P*NM'5Y7SHRE_VBE03:/]A!^ M@XXY60_M&"B4OV.K*ZO_ECV"C8;VV'7>.S5ZNTW2[K8Y$?#N2&C>]X^-$/J6 MRB!Q< B=N@?J&VPEHTKJ!,6^^8[GVY ?7/BS8++1\:[2(47LEF%8$8XWHH@C MMU%??GT,;@>^'9R;],BM=C)I+P=3;K2+C"ZA?0>^HH9*9E 1G<\9&X6M!!92 M^ (N'L6B\XS09M[71.N$N75"&ULU5U=;^.X%7TOT/]@N,^. MXF2GVP23+CR>I#!V9N+&V6[;EX"6:)D(11HD%=O_OJ0^',GBE>1MPDAY2&SY MD#SW'(KBE4CG\R^[B Y>L)"$LYOA^.Q\.,#,YP%AX>M]UNS[:79UR$ MWL7Y^=C[]_=O"W^-(S0BS-3GXV%>RM1B*S>^NKKRDD]S: 6Y6PJ:MW'IY70. M->M/ W4H4 1_\M(/BU!24W6!M"37,HGD&_>12I1K9#0 $>;=*(>-S*'1^&)T M.3[;R6"HA1[HGU1LP2E^P*N!^?O;P^S0:DCY$C.\E5LB\)G/(\\@O"G7QFJZ M2=FUP*N;8F#PT'64#&^0RV$*4]#O0SC62MX?]Z'QD8!CQ Y MD72UM /&24NC"$=+8_=)=,M%WY\KHO0TADF!]^?%N)J<2BTOX[1/XA6*J?K# MG3(O7N:L#Q-&S&#W3;\M\<8[A5F @YRYJ?"DL4D194JI@JF1\9F2.)EMF! MIX5""AL:.F0\TR]EW@!%2TR39I\RL WK?2SK1[1\[4XUC#/<,=M7QRAC(XBGW8,#;7 MU6 A<-#."BO\R7;F=\D-F#4XEKV)(1+[9R%_\0),4B_TBU<+])NG?.KZJ&NT MJ*XA1<333Q\C=/,:3& (W5$4VK4M03HM;I7INTZ(3E#W M*Y:^(!M5F/P!(A>0_=#ZF# X6+@=*QYP2*02R;W$0T#U@X>U2*=-:&8.SFG< MNC%A+$;T 6^X:#"AB.R%]A7"D.0_N97\GS$2"@NZ;Z/Z$;@7PMLX0]I_V$!0!LRX>>/,^'V MQ4P4=&CM?3@4Z9T59>:0&W]SZ\8<"\(#'9-HX<,1N!<.V#A#VE]]A/:W+&BK M? ;MD>Y%QG6/#%S(/HV%,#D@D3ZB_\%(U"H/H3LM?BWI][U]UJS_+5-$[>\( MQ3]BX#Z9AAVC.JVWE2RHLZ-,-R65IWY,_4 1T,=MR![H;2$,:NXHGTV)335] M@>B,!7CW*][7B7X$[8'J-L:@[(YRVI397) (B?V"^,T#RS&V!\);*8/*.\IH M4VJ/:#<+=!!D1=+5>2\>^19X^@B ^R/_$6=0 M?*9>S 5_(>EFAR8'CDKTQP8;<= +IVERWD_2Z4*;LR!%]D?[(F%0 M'[HW^5-NB"HZPYZQ'F-@JT[*0$Z;365::@O(Y2 M8W/-F0B,X&Y=1'1;W&.BH+:.\MQON@XZ7W-6>P_Y&-5IC:UD09U=I:MFGY$$ MAX?#QYU6MLP2E-11^OF[($KS,6N;8Y;=0;)M0]%8*[334L.,0=D=I9P+3HFO M%6+A=QV'((C:-:_B.BTX0!=2^VVV*C2K/1?8] &L)_G)8B"S65'J#W2\I"1&\(ZJF0"_4AWB#1CC*3]/]*C.VXB)*6-WI%W8+K-!. MBP\S!F5WE)].XH H'*0$[PA#S-?)W"$HX Y!4ZENF]&&/.2++;#W>U3Q.Z;T M5\:W;(&1Y P':6)1][0"*-)I1YJ9@W8X?7+Z+TYCII!(EMP*X-RP0GL@OXTQ M*+O3AZ39LO+#EJ;R_1 Q-JB(->.'UX.F,*"^0K\H*_(H4ROG5>V$OT MP(L:XJ 73A<>)R?J5,<3\OJU R5@#Y2O\@4%=[K>>!$A2K_$4@<@:\>?$K ' M@E?Y@H([75%\&V$1ZF'P'X)OU3K;R%@GO+5 #PR >8-&.%TY?+M[W5B=;JVK M=:&"[H,%=M*@_HYWRDY\WRPU2><$+$ "< #&=]J#!MJ@"X[2Y'NUQJ(X*TNH MF6#J%H(TE>JT(ZW(0[Y\YUUZ6"[A.:P_0!=5VF@7/XR4E_AWEJ';> M7X#U0.MCMJ#43C/?+X@]BWBC_/U<JZ?7#46[[17IT4!6E9(O3][1P'JYI_U9]EQ\\O\RPM]Y']0 M2P,$% @ %$!05V=1T?"6"@ F(4 !0 !G;GCYSS?7DPF;V]O)V]G)XRO)]//GT\G__SY=A$]DPT>)U36%Y&1 MBI*UV.).S\_/)T6IDAK*_8JG:A]G$V6GKEF4)AWZAI,LN<@*>["2.'A+_RB/(64H>R1,JFGF1'[;B$&?)9IM* M4\6V9TZ>[&92SB>M MNJJ@B6NS#X0G++ZF'W.M1WNRO\@QS_^'!C3CG3=AR7*6^QKY:ZZV&I+]7&K,(A.MCG2>[G6("GRUP M7DA,J?/3#<"L<>JAZ8+B!# 'GY+4>K^D+)Y)FL[89HMI_X!B$[NF!3:L\V(J M@R(&M I<+),&-K:A]PF/8;N+GUH<+$*ZPX$4%6%(QGDB MJ7$;HH0E5*."KU_2*YI/ B16N<'$,VF'8]*%" < M;6=]: BU3S!NDBS":>GE1FS+.IIGT;H&!+2K0V((@P(%<@?"4@8H9HH0K\#\ MBV ^#)>&T@\LAE4[*K4L0%!T;WV82+T72&8[SENNX1D'ECJ[*=MCMKX_"^B" M *7'G''7MI2W0/$T UW3/,D/-TE*[G:;%>&6QID25VQ YA03>GD0+ "F= 9* M&9(Z5 J]]+RZ2T#S.[RQC1!VF5L"[";;%+0U 9%@-0;0<-0B*?9"Q$R,3!RG MJ<(4 MND4#,MIF0U<%! =@#:"C4J/%?.9S)EGB_3P6H"9/2?D\> \EH-XM+#VVV\P MXH#0Z78($"2"4#O*)TAS&C&^98W''69L)P; PXS%\ JE)\HM5(.:T$:K,R0@ MP(;X!#!KA7XJGTE!C*.J B1K\$+<51R+ Y55_]TFE)R"[;=JW=+58;?-E$48 M$$FP.X"?2OE)?4 R!MW34*"9OJ.I4__03(=",PT:FNE'H%F^L4"@.7M'4\_\ M0W,V%)JSH*$Y^Q THN.]CC4S\?&>+]F;[>%L4.D%&=.J%9BC+#Q<#&]]L,@ MN9Z1(3XQ*196]_R!L]>$1O"2&9)[ 08P;:5&TX:'CMU@'S_U@EC%>1UKRD5Y M[Q^)DOD99=HF[4-,J0D/DK:QWL&E5/M$XH%E.4[_G6P[3\3M8B]X6 U;(6DI MPT/%9J\/F#(&B2 ?)]85KO*&AO55,JW;AHP>+OZNA<;''[+,[I(^/#,*/R!@ M2ESU-&1.];9>'D2/ Z;T7B]DJ-!YNAHO,TQD]N&[4>9L9M?MU!.Y*@BB=W4W MQC2MRAWWYF\\R<6>9VRSV='J+H_MN4% YZJ7.VVJ'K>*@NC]+FK+.]EUB5U#T&U9PP,H@(.FUI\,B L91(P*5(:B(\8O-/,MV MA+\+'DN()X1 \P!(ACY$G""3O5"5@3[96I!H)^;'P^ETM4SRU'9R:4JY'OIM)O7AOZD) H$.8\9)225%2NOCA83CE+7N7P2L MO2T"UCV+@'6(BX#UT$7 VMLB0.VV3!$BQJ7[59JL,9"[.,E)7)JY22BF48+3.CVB[8IX?X@S6@::K\'IT8?!T#"3 M!DYEF,IE6 <>4UVZOI1>/H#Q&TG3GRA[HPN",T9)7%Y+L=TIZM:[?6*FQW;[ MH1E ' 1.0QP"C\[(H/&+C$(JK+H2YH6D7UFZHSGFQ;ODW#8R 3JWY VV\1H MHH!(L3L#"*G%J%3[>4&[S!Y1+[+D@&=- =,M=_RZ=J=I[:UMJS8@9CH-0N]P M5SD_CFOC,LK3*Y8YD=\7D;R2;SC'E3>PO9#<]4N57:;UMREMVH 0ZC0(OC]9 MQ\A4,5@QY2UE#)^)I=::=3PEKJG<)XXQ+)JY8VI)0'C8?'5DD.%(:;VPL-C@ M-/VZRQ)*,G@BTE1N6;!:;+/0D@3$@LT7P$(A14KKA87K#>%K,;W]@[.W_+G* MSPJV#5"[9:/3(G7$CE>&5L,:@OC MAB((1D!;T+*X^5T!?G+G[59I$MVD#,-765H:QQGS3'M:LKRC(" "3%=0BKQ" MB JEE_[_BND+WVWSZ/# 642(?,HJJT>KONMO Z/=,O.N)K5I&A0:$&?O\0L0 M>*P"->KXU)BQ?%[,DP^-RVQN+'I9/&-Q .]W>29G4&$,O@K>&>3X]L* !F@W M&3HB D)O@$WHAD,1B8K03Z@,1HUH3^=GV3$+((F_'A[)$^'RO8,EV>=?Q8Y> M.LXP!L2Z/GL;W!S]9*XW, @(W^L6.M7+4+,"M)+/B%55H-]E):BHQ?;]Y,M5LZ(R(F7 IZTQ:R_>'W'W]XSYEX MN;:_9D33EEF/T-=KS6[:BRQ;7G>[J]7J8C6XD"KI]B\O>]U_/C],H@5-28<) MN[Z(MG>M[%I<[7I75U?=XMN=]$2YGBF^V\:@NPMGOV;S+0OH#R+1[%H7X3W( MB&0%CMK-M+P*^U]G)^O819U>OS/H7:QUW#;T6N:G)*@DI\]TWK)__WH>[[>: M<#FC@J[TBBEZ$*SF_:B5B9+?2N+GN7Q?I_JFBRS=(D M3;-TR8W-;F7;2T4U%5EA]\$LJ#2AZXR*F,:[%=G-GQ5=QC+;XK+\Z;4ZK8\R MRE.S0?.Q5&ZCV<7#950)@=M4R".[-@)M0BB :QI=)/*U&U-FP/<']D/'?BA MF'^^%1NZG>E,D2C;K8F3&>7%^K\9S9&DVT!4.Q)3LT9W4%7%<4R'F;M544NJ MF"K#>K@C*;:(;FK=E^ M;&,8<9*X<1Y)@#Q[&$"=;K"(?J0Z4FQIN=2 K2B!?/NH?!W>&L:\.W:>:<)L MO#:4B:%$[<)PO^!I @0_P.PI@FZ1,G K1$[X,UU*50.^J@3R_AF3M\L;$N8_ M=W9"S; MC!BG7_)T]OW&:97UJ0K*&*7H])E"8;N[TR"R+R3U[,MN)90Q2JT9,H?">6C\ M*,+'(J;K3W03 GTBA9)&J3&#]E!0/RF6$K69L*B^TSC50F&C5)9A@RBTIV0] MCHTK-F?E4\%ZZ-XF4/8H927(+DH*QB*2:BD/;A89UE&2_GE@@O9"J7#*P<^(\!(0L/E&L/?/P]Z'8T>I0VMMOA'L M@_.P#^#846K16IN8V(?FXZ.:RI7G";17#$6.4HO66,0$7IQI'M63DJ^L'!Q5 M1_VD!10]8HD:-HNZPYOE-">2.6JVYSF)R?I,X(_X\MZZXDW7HH<\3" M-62TZ1N,9=[M30O?4*(C"90O2JWJM-,T4IMA18E_]ZTJH$!1"E"7F89Y/DC[ M[&,A1?!^[*D*RA6EDO29:KKCM:.)M??0/_@:/((-I5L]MM$PQJ^*92:"H4S3 M7&SOT7B>BGFD4+PHY5_07L.H)Y*SB&5,))_-%:)BA+LYNW10R"C%GM]8PX2? M%+69IN:RNQC'9:<;J,?YW-?SAO10XBBU7KU17/)CK7.JSN7O: 7- DK9!S7= M=#]#H]QT>YM>?S:U,V8\O3SF6J8[1E(K/9PJ);3DVW!Q1CS/.$N*?219L )YG@TD\8+7I^7O%E)^QF$N5 M%G&,S 7_NL0>A;Z1\N 44/.)#Q+!9I/%I&;4QLU?ZD61D M&V&(OZ\%E#_B \6P6;3Q\VIH3CR)##\S/Q)":2,.A75:0X$\20GG=[EF@NI@ MWW(DA$)&'//JM(8"^3ZE*C&=VA]*KK+%=FYG"+:G 10ZXLC6H%4<^.OO\\C+ M^6]!\@XU^.T$B-B])K%>NQ%%=B!%>287,5$>ZB$]E#OJQ$J_T8;)/V8+J@ZO MGXI@QJ9N"PUZJ&\%S0)*N0HUC7-N/9C)'SRU5G10WHB%J\=$2\J7V;1YDG)B%+[^$3OCS9 001< 30EB/7I62AP M;A?(-+63B63T,ED8T_HQSXK7>YKX@C<-@NV@J<&:9 MSJFRPQ2F=)W=F0V]A"^* ,VA^4%]HQ 8@R--[[LGOA[, ONBVO(;^\N^C-4L M^1]02P$"% ,4 " 40%!7W4:31:@- !B(@ "P @ $ M 97AH7SDY,2YH=&U02P$"% ,4 " 40%!7 T<4+R - "@. #@ M @ '1#0 9CAK7S$P,34R,RYH=&U02P$"% ,4 " 40%!7 MA257J[ " #5"P $ @ $=&P 9VYW+3(P,3DP,3 Q+GAS M9%!+ 0(4 Q0 ( !1 4%>O[VJ!40@ (=D 4 " ?L= M !G;G